John M. Burke, MD

Articles

Dr Burke on Ongoing Investigations in Lymphoma Treatment

June 11th 2024

John M. Burke, MD discussed ongoing investigations into the treatment of lymphoma that were presented at ASCO 2024.

Dr Burke on Treatment Paradigm Shifts in Relapsed DLBCL

September 7th 2023

John Burke, MD, discusses the evolution of the diffuse large B-cell lymphoma treatment paradigm.

Dr Burke on Ongoing Investigations of Targeted Therapy Regimens in MCL

July 20th 2023

John M. Burke, MD, discusses several ongoing or upcoming investigations of targeted therapy in mantle cell lymphoma.

Dr Burke on the Influence of the SHINE and TRIANGLE Trials on Ibrutinib Use in MCL

June 15th 2023

John M. Burke, MD, discusses the influence of two key BTK inhibitor combination studies on therapeutic approaches for patients with previously untreated mantle cell lymphoma.

Dr. Burke on the Underrepresentation of Elderly Patients in Clinical Trials for Lymphoma

December 19th 2022

John M. Burke, MD, discusses the underrepresentation of elderly patients in clinical trials for lymphoma.

Dr. Burke on POLARIX Data Examining a Polatuzumab Vedotin–Based Regimen in Newly Diagnosed DLBCL

December 14th 2021

John M. Burke, MD, discusses findings from the phase 3 POLARIX trial in patients with newly diagnosed diffuse large B-cell lymphoma.

Dr. Burke on Risk Stratification Strategies in Follicular Lymphoma

September 28th 2020

John M. Burke, MD, discusses risk stratifications strategies in follicular lymphoma. 

Dr. Burke on Treatment Options in Relapsed/Refractory Follicular Lymphoma

September 25th 2020

John M. Burke, MD, discusses treatment options in relapsed/refractory follicular lymphoma.

Dr. Burke on the Potential of Time-Limited BTK Inhibitor Therapy in B-Cell Malignancies

September 23rd 2020

John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.

Dr. Burke on Treatment Options in Low-Tumor Burden Follicular Lymphoma

September 16th 2020

John M. Burke, MD, discusses treatment options for patients with early-stage or advanced follicular lymphoma with a low tumor burden.

Dr. Burke on Tazemetostat’s Mechanism of Action in EZH2-Mutated Follicular Lymphoma

August 22nd 2020

John M. Burke, MD, discusses the role of tazemetostat in EZH2-mutated follicular lymphoma.

Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies

July 20th 2020

John M. Burke, MD, discusses current indications for BTK inhibitors in B-cell malignancies.

Dr. Burke on Research With Tafasitamab in Lymphoma

May 9th 2020

John M. Burke, MD, discusses research with tafasitamab (MOR208) in lymphoma.

Dr. Burke on the Ongoing First-MIND Trial With Tafasitamab in DLBCL

March 27th 2020

John M. Burke, MD, associate chair of the Hematology Research Program for US Oncology and medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses the ongoing phase Ib First-MIND trial in diffuse large B-cell lymphoma (DLBCL).

Dr. Burke on Findings of GOYA Study for Diffuse Large B-Cell Lymphoma

February 24th 2017

John M. Burke, MD, Rocky Mountain Cancer Centers, discusses the significant findings of the phase III GOYA study investigating obinutuzumab (Gazyva) plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Dr. Burke on a Study Investigating Obinutuzumab in Large B-Cell Lymphoma

December 5th 2016

John M. Burke, MD, discusses the GOYA study, a phase III study investigating obinutuzumab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma. Burke discussed the study during the American Society of Hematology (ASH) Annual Meeting.